Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) Research & Development (2016 - 2025)

Northwest Biotherapeutics (NWBO) has 16 years of Research & Development data on record, last reported at $7.4 million in Q3 2025.

  • For Q3 2025, Research & Development fell 8.36% year-over-year to $7.4 million; the TTM value through Sep 2025 reached $33.8 million, up 6.08%, while the annual FY2024 figure was $34.9 million, 25.81% up from the prior year.
  • Research & Development reached $7.4 million in Q3 2025 per NWBO's latest filing, roughly flat from $7.4 million in the prior quarter.
  • Across five years, Research & Development topped out at $13.6 million in Q2 2022 and bottomed at $3.7 million in Q3 2021.
  • Average Research & Development over 5 years is $7.5 million, with a median of $7.4 million recorded in 2025.
  • Peak YoY movement for Research & Development: plummeted 78.78% in 2021, then skyrocketed 150.32% in 2022.
  • A 5-year view of Research & Development shows it stood at $4.2 million in 2021, then skyrocketed by 123.41% to $9.4 million in 2022, then decreased by 20.3% to $7.5 million in 2023, then surged by 41.17% to $10.5 million in 2024, then dropped by 29.2% to $7.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $7.4 million in Q3 2025, $7.4 million in Q2 2025, and $8.4 million in Q1 2025.